Member Info for inanaco

I explained earlier that IFN-Y was part of the amplivant adjuvant ... what i should have explained its a secondary effect

TLR recognize distinct structures in microbes, often referred to as “PAMPs” (pathogen associated molecular patterns). Ligand binding to TLR invokes a cascade of intra-cellular signaling pathways that induce the production of factors involved in inflammation and immunity (4, 5)

but i didn't want to over complicate ...

Web Site ....

http://www.isa-pharma.com/technology/amplivant-technology/

Crumbs .. only corners ..... not U turns ..

Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion

Interferon-gamma is secreted predominantly by activated lymphocytes such as CD4 T helper type 1 (Th1) cells and CD8 cytotoxic T cells (23–26), ?d T cells (27–33), and natural killer (NK) cells (34, 35) and, to a less extent, by natural killer T cells (NKT), B cells (36–39), and professional antigen-presenting cells (APCs)

https://www.frontiersin.org/articles/10.3389/fimmu.2018.00847/full

Please find a mechanism that shows how a trial of SCIB1 can fail ... because I cannot !! every trial or product i look at all have this one common denominator ..

if IFN-y is involved ... something is happening in the cancer

so whe have Proof already in patients that Immunobody induces IFN-y ...

that IFN-y ... has a counter response the Cancer tries to turn off the t cells with its PD1 ligand

so SCIB1 plus a mechanism the knocks out that ligand ... is Keytruda ....

so the Science says the trial cannot fail, and if it could i cannot find the mechanism ...

opps ...........correction

""so these T cells are not programmed"""

NOT should not be there ..LOL it should be ""Now"

is shown you .... actual data generated by Oncosec trials ... IFN-Y and they have shown the importance of it ... linked back to BioNtech and Scancells technology ...

which is why i keep saying that ... Sancells Technology should work because it cross references to other trials which have worked ....

so Scancell Moditope Vaccine (modi1) does two things ...

it floods the Dendritic cell with IFN-y ... using ISA amplivant technology
and it gives the codes "epitopes" to the cell to engage T cells ...

so these T cells are not programmed to go after Moditope epitopes on the cancer and have been hit with a cytokine that has changed the Cells Phenotype to a Pro Inflammatory .. ie .. if you find a moditope target, give off your own Cytokine IFN-Y .. to attract others by inflaming the tumor ..

Now Onconsec .. are using Il-12 to activate more IFN-Y

Interleukin 12 (IL-12) is produced by activated antigen-presenting cells (dendritic cells, macrophages). It promotes the development of Th1 responses and is a powerful inducer of IFN? production by T and NK cells

Now if you look at the T cells Scancell Immunobody and Moditope Produce

TH1 ........................

tick tock

Hot tumors often have a high mutational load. That is, they have many changes in their DNA code that cause the cancer cells to produce distinctive new molecules called “neoantigens” on their cell surface. These neoantigens make the tumor more prone to recognition by the immune system, and thus more likely to provoke a strong immune response.

“Cold” tumors, by contrast, are cancers that, for various reasons, haven’t been recognized or haven’t provoked a strong response by the immune system. Immune T cells have been unable to penetrate such tumors. The T cells have been excluded by components of the microenvironment. The microenvironment in and around tumor cells comprises blood vessels, structural elements, and specialized immune cells; the latter include myeloid-derived suppressor cells and regulatory T cells, or Tregs. These Tregs turn down the volume on the normal immune response by secreting immunosuppressive chemical messengers like cytokines that impede the movement of T cells into the tumor. The result is what some have called an “immune desert” around the tumor.

https://blog.dana-farber.org/insight/2018/06/enhancing-immunotherapy-race-make-cold-tumors-hot/

Inject that MRNA into a cancer that is Cold ... ie has no immune response to it ...

you would instantly cause stress on the cancer giving rise to Moditope epitopes being displayed ...

the same cytokine would attract moditope CD4 killer t cells to the site ...

leading to destruction of a cold cancer

then can you see why i am interested ...

IFN-y ............... drives Moditope

it's a cytokine

can you now see why BioNtech are interested ?

“The idea is to inject mRNA encoding immunomodulatory cytokines directly into the tumor, and actually cause the tumor to secrete cytokines that then attract and educate T cells to kill the tumor, but also to generate memory, such that related T cells can travel to sites different from where you inject it, to also, if they see metastasis at a different location, remove that metastasis,” Marett said.

T cells have no brain ...
Dendritic cells have no brain
in fact the immune system runs independent of a brain

but cells talk by chemicals ... ""cytokines""

and they identify by """ epitopes ""

read that and what is the major element that pops up at you ?

Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-? and IL-12"

https://en.wikipedia.org/wiki/Interferon_gamma = IFN-Y

Do you understand the principle behind Oncosec

https://ir.oncosec.com/press-releases/detail/1975/oncosec-announces-publication-of-new-research-in-the

LOL ..... it's not that C7 .. the reply would run to pages and pages

explain . Gulp ....... i have been for years LOL

So its conceivable BioNTech can supply antigens to work with our vaccines?

No ...

you may think what has that to do with Scancell .................well think Project Blueprint

well ..inflammation caused by Cytokines ""Interferon gamma"" .. induces stress which causes cells in the tumour to citrullinate and to display "moditope"

so patients with NO inflammation or immune response ... all of a sudden have cancers highlighted ..

what the market is not doing is putting a jigsaw together .... but Scancell is the beating heart of it ... moditope

the key to understanding ................... Project Blueprint is when you see statements like this

“The idea is to inject mRNA encoding immunomodulatory cytokines directly into the tumor, and actually cause the tumor to secrete cytokines that then attract and educate T cells to kill the tumor, but also to generate memory, such that related T cells can travel to sites different from where you inject it, to also, if they see metastasis at a different location, remove that metastasis,” Marett said.

https://www.genengnews.com/news/biontech-to-acquire-mab-discoverys-antibody-generation-unit-building-on-six-year-collaboration/

why should it .......... Most of the time projects are looking to discover a target antigen ... or mobilise the existing immune system or attract T cells to the Tumour with signaling ....

all great ...all seems to work ............. but never in enough patients